Women’s Health Care Market: Information by Drug (Vagifem, Lupron, and Yasmin), Application (Hormonal Infertility, Postmenopausal Osteoporosis, Endometriosis), and Region—Forecast till 2029

Feb 17, 2021   Women go through certain unique health care challenges and are more likely to be diagnosed with certain diseases than men. The leading causes of death among women are chronic diseases and conditions such as cardiovascular diseases (CVD), cancer, and diabetes. Therefore, there is a high demand for women’s healthcare. Thus, the women’s health care market is predicted to grow with a CAGR of 14.0% during the forecast period. Growing Number of Aging Women across Globe Aging women make...
Request Free Sample Report

Report Description

Women go through certain unique health care challenges and are more likely to be diagnosed with certain diseases than men. The leading causes of death among women are chronic diseases and conditions such as cardiovascular diseases (CVD), cancer, and diabetes. Therefore, there is a high demand for women’s healthcare. Thus, the women’s health care market is predicted to grow with a CAGR of 14.0% during the forecast period.

Womens-Health-Care-Market

Growing Number of Aging Women across Globe

Aging women make up a significant proportion of the world's population and with constant growth in number across the globe. As per WHO, the number of women age 60 and over will increase from about 336 million in 2000 to over 1 billion in 2050. Women outnumber men in older age groups and this imbalance increases with age. There are a variety of “determinants” that surround individuals, families, and nations to determine a person’s active aging. These determinants affect well-being directly or indirectly.

The determinants of active aging are interconnected in many ways and the relationship between them is important. For example, poor women (economic determinant) are more likely to be exposed to inadequate housing (physical determinant), societal violence (social determinant), and not eat nutritious foods (behavioral determinant). Therefore, increasing the risks for women’s health and thus, leading to boost the market growth.

Figure 1: Determinants of Active Ageing

Determinants-of-Active-Ageing-Updated

Source: Active Ageing: A Policy Framework, WHO, 2002 (www. who.int)

Increasing Chronic Illness in Women Impacts the Market Growth Positively

The three leading causes of death in older women are heart disease, cancer, and stroke. Heart disease is the prominent cause of death in women age more than 60. Most women in the age group of 75 through 85 are more prone to osteoporosis. According to the National Osteoporosis Foundation, across the globe, osteoporosis affects more than 8 million women over age 50. The risk of osteoporosis increases in women during the post-menopause period and causes 2 million fractures for USD 19 billion annually, and costs will rise as the population ages. 

Moreover, about one in five women over age 65 are affected by some type of cancer. Cancer is the second-leading cause of death for senior women. Most of the newly diagnosed breast cancer cases are in women over the age of 60, while the incidence of ovarian cancer peaks when women are in their 70s. Furthermore, Stroke is the third leading cause of death for American women. The Centers for Disease Control and Prevention evaluate one in five American women suffer from stroke and more than half of women who have a stroke die from the event.

Also, Diabetes the seventh leading cause of death in the United States can lead to serious and costly complications, including heart disease, stroke, amputations, blindness, and kidney disease. Women with diabetes have a higher risk of heart disease, blindness, and depression than men do. Alzheimer's disease in women is twice as probable to get it than men.

Depression affects twice as many senior women are affected by depression than men, most commonly between ages 40 and 59. Arthritis affects more than half of all seniors over the age of 65 have arthritis, and women are more prone to it than men. Obesity is a major concern affecting nearly 41 percent of women between the ages of 65 and 74, putting them at risk for several diseases. Thus, contributing to the growth of the women’s healthcare market.

Growing Demand for Contraceptives to Prevent Unintended Pregnancies Contributing to Market Growth

According to WHO, in 2016, in developing countries such as Asia, Africa, South America, there were around 21 million pregnancies among adolescent girls aged 15–19 years. An estimated 23 million adolescent girls have an unmet need for modern contraception and are at risk of unintended pregnancy. Considerable gaps persist in the use of modern methods among couples who want to prevent pregnancy.

In 2015–2017, 64.9% of the 72.2 million women aged 15–49 in the United States were using contraception to avoid unintended pregnancies. Growth in contraceptive demand until 2030 is expected mainly in the regions of sub-Saharan Africa and Oceania. Between 2015 and 2030, contraceptive use is projected to grow particularly in regions where less than half of married or in-union women of reproductive age currently use contraception. Thus, boosting the market growth.

Women’s Health Care Market: Segmentation

Prolia Drug Segment to Dominate the Market during the Forecast Period

Based on the drug, the global women’s health care market is majorly segmented into Prolia, Premarin, Mirena, Forteo, NuvaRing, Lo Loestrin Fe, Makena, Vagifem, Lupron, Yasmin, and others. The Prolia drug segment accounted for the largest share of the women’s health care market. Prolia is a prescription treatment used for treating postmenopausal osteoporosis, who are at high risk for fracture or weakness in the bones. This medication works by decelerating bone loss to better maintain strong bones and reduce the risk of broken bones (fractures).

Denosumab belongs to monoclonal antibodies a class of drugs, used to prevents certain cells in the body called osteoclasts from breaking down bone. The large share of this segment can be attributed to the rising aging women population. Thus, the increase in women falling under the risk category of menopause, thus contributing towards the upsurge in demand for Prolia drug.

Regional Overview

North-America-Lead-Womens-Health-Care-Market

North America to Dominate the Women’s Health Care Market during the Forecast Period

North America dominates the women’s health care market as the region is supported by the increasing aging women population, growing prevalence of diseases like postmenopausal osteoporosis, increasing median age of first-time pregnancies, and increased healthcare spending in the US and Canada. According to the National Osteoporosis Foundation, of the estimated 10 million Americans with osteoporosis, about eight million or 80% are women.

As estrogen, a hormone in women that protects bones decreases sharply when women reach menopause, which can cause bone loss. Therefore, the chance of developing osteoporosis increases as women reach menopause. Also, the high awareness and understanding regarding the use of contraceptives and sex education among women and the easy access to modern contraception as compared to developing countries propel the market growth in this region. Besides, the local presence of key players, high disposable income, and lifestyle changes accelerate the regional market growth.

Key Players

  • Amgen Inc. (US)
  • Pfizer Inc. (US)
  • Bayer AG (Germany)
  • Merck & Co. (US)
  • Allergan (Dublin)
  • Eli Lilly And Company (US)
  • AMAG Pharmaceuticals (US)
  • Novo Nordisk A/S (Denmark)
  • AbbVie Inc. (US)
  • Johnson & Johnson (US)

Recent Developments:

  • Digitalization of women’s health through the platform of Femtech, motivating women to access and use applications for managing health issues. Femtechcontinues to serve the purpose of addressing the health and wellness needs of women through software, diagnostics, products, and tech-enabled health services.

Women’s Health Care Market: Segmentation

By Drug

  • Prolia
  • Premarin
  • Mirena
  • Forteo
  • NuvaRing
  • Lo Loestrin Fe
  • Makena
  • Vagifem
  • Lupron
  • Yasmin
  • Others

By Application

  • Hormonal Infertility
  • Postmenopausal Osteoporosis
  • Endometriosis
  • Contraceptives
  • Menopause
  • Polycystic Ovary Syndrome
  • Other application

By Region

  • America
    • North America
      • The U.S.
      • Canada
      • South America
  • Europe
    • Western Europe
      • Germany
      • The U.K.
      • France
      • Italy
      • Spain
    • Eastern Europe
    • The Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Korea
    • Australia
    • South Korea
    • The Rest of Asia-Pacific
  • The Middle East and Africa

Frequently Asked Questions (FAQs)

A growing number of aging women across the globe, increasing chronic illness in women, growing demand for contraceptives to prevent unintended pregnancies are the key factors expected to drive Women’s Health Care Market during the forecast period.
Amgen Inc., Pfizer Inc., Bayer AG, Merck & Co., Allergan, Eli Lilly And Company, AMAG Pharmaceuticals, Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson are the top players in Women’s Health Care Market.
North America is expected to hold the highest market share in Women’s Health Care Market.
Prolia Drug Segment is expected to be the leading segment in Women’s Health Care Market during the forecast period.
The women’s health care market is predicted to grow with a CAGR of 14.0% during the forecast period.
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times and included in every purchase.
We will send you an email with login credentials to access the report. You will also be able to download the pdf.
Basically, choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.

Women go through certain unique health care challenges and are more likely to be diagnosed with certain diseases than men. The leading causes of death among women are chronic diseases and conditions such as cardiovascular diseases (CVD), cancer, and diabetes. Therefore, there is a high demand for women’s healthcare. Thus, the women’s health care market is predicted to grow with a CAGR of 14.0% during the forecast period.

Womens-Health-Care-Market

Growing Number of Aging Women across Globe

Aging women make up a significant proportion of the world's population and with constant growth in number across the globe. As per WHO, the number of women age 60 and over will increase from about 336 million in 2000 to over 1 billion in 2050. Women outnumber men in older age groups and this imbalance increases with age. There are a variety of “determinants” that surround individuals, families, and nations to determine a person’s active aging. These determinants affect well-being directly or indirectly.

The determinants of active aging are interconnected in many ways and the relationship between them is important. For example, poor women (economic determinant) are more likely to be exposed to inadequate housing (physical determinant), societal violence (social determinant), and not eat nutritious foods (behavioral determinant). Therefore, increasing the risks for women’s health and thus, leading to boost the market growth.

Figure 1: Determinants of Active Ageing

Determinants-of-Active-Ageing-Updated

Source: Active Ageing: A Policy Framework, WHO, 2002 (www. who.int)

Increasing Chronic Illness in Women Impacts the Market Growth Positively

The three leading causes of death in older women are heart disease, cancer, and stroke. Heart disease is the prominent cause of death in women age more than 60. Most women in the age group of 75 through 85 are more prone to osteoporosis. According to the National Osteoporosis Foundation, across the globe, osteoporosis affects more than 8 million women over age 50. The risk of osteoporosis increases in women during the post-menopause period and causes 2 million fractures for USD 19 billion annually, and costs will rise as the population ages. 

Moreover, about one in five women over age 65 are affected by some type of cancer. Cancer is the second-leading cause of death for senior women. Most of the newly diagnosed breast cancer cases are in women over the age of 60, while the incidence of ovarian cancer peaks when women are in their 70s. Furthermore, Stroke is the third leading cause of death for American women. The Centers for Disease Control and Prevention evaluate one in five American women suffer from stroke and more than half of women who have a stroke die from the event.

Also, Diabetes the seventh leading cause of death in the United States can lead to serious and costly complications, including heart disease, stroke, amputations, blindness, and kidney disease. Women with diabetes have a higher risk of heart disease, blindness, and depression than men do. Alzheimer's disease in women is twice as probable to get it than men.

Depression affects twice as many senior women are affected by depression than men, most commonly between ages 40 and 59. Arthritis affects more than half of all seniors over the age of 65 have arthritis, and women are more prone to it than men. Obesity is a major concern affecting nearly 41 percent of women between the ages of 65 and 74, putting them at risk for several diseases. Thus, contributing to the growth of the women’s healthcare market.

Growing Demand for Contraceptives to Prevent Unintended Pregnancies Contributing to Market Growth

According to WHO, in 2016, in developing countries such as Asia, Africa, South America, there were around 21 million pregnancies among adolescent girls aged 15–19 years. An estimated 23 million adolescent girls have an unmet need for modern contraception and are at risk of unintended pregnancy. Considerable gaps persist in the use of modern methods among couples who want to prevent pregnancy.

In 2015–2017, 64.9% of the 72.2 million women aged 15–49 in the United States were using contraception to avoid unintended pregnancies. Growth in contraceptive demand until 2030 is expected mainly in the regions of sub-Saharan Africa and Oceania. Between 2015 and 2030, contraceptive use is projected to grow particularly in regions where less than half of married or in-union women of reproductive age currently use contraception. Thus, boosting the market growth.

Women’s Health Care Market: Segmentation

Prolia Drug Segment to Dominate the Market during the Forecast Period

Based on the drug, the global women’s health care market is majorly segmented into Prolia, Premarin, Mirena, Forteo, NuvaRing, Lo Loestrin Fe, Makena, Vagifem, Lupron, Yasmin, and others. The Prolia drug segment accounted for the largest share of the women’s health care market. Prolia is a prescription treatment used for treating postmenopausal osteoporosis, who are at high risk for fracture or weakness in the bones. This medication works by decelerating bone loss to better maintain strong bones and reduce the risk of broken bones (fractures).

Denosumab belongs to monoclonal antibodies a class of drugs, used to prevents certain cells in the body called osteoclasts from breaking down bone. The large share of this segment can be attributed to the rising aging women population. Thus, the increase in women falling under the risk category of menopause, thus contributing towards the upsurge in demand for Prolia drug.

Regional Overview

North-America-Lead-Womens-Health-Care-Market

North America to Dominate the Women’s Health Care Market during the Forecast Period

North America dominates the women’s health care market as the region is supported by the increasing aging women population, growing prevalence of diseases like postmenopausal osteoporosis, increasing median age of first-time pregnancies, and increased healthcare spending in the US and Canada. According to the National Osteoporosis Foundation, of the estimated 10 million Americans with osteoporosis, about eight million or 80% are women.

As estrogen, a hormone in women that protects bones decreases sharply when women reach menopause, which can cause bone loss. Therefore, the chance of developing osteoporosis increases as women reach menopause. Also, the high awareness and understanding regarding the use of contraceptives and sex education among women and the easy access to modern contraception as compared to developing countries propel the market growth in this region. Besides, the local presence of key players, high disposable income, and lifestyle changes accelerate the regional market growth.

Key Players

  • Amgen Inc. (US)
  • Pfizer Inc. (US)
  • Bayer AG (Germany)
  • Merck & Co. (US)
  • Allergan (Dublin)
  • Eli Lilly And Company (US)
  • AMAG Pharmaceuticals (US)
  • Novo Nordisk A/S (Denmark)
  • AbbVie Inc. (US)
  • Johnson & Johnson (US)

Recent Developments:

  • Digitalization of women’s health through the platform of Femtech, motivating women to access and use applications for managing health issues. Femtechcontinues to serve the purpose of addressing the health and wellness needs of women through software, diagnostics, products, and tech-enabled health services.

Women’s Health Care Market: Segmentation

By Drug

  • Prolia
  • Premarin
  • Mirena
  • Forteo
  • NuvaRing
  • Lo Loestrin Fe
  • Makena
  • Vagifem
  • Lupron
  • Yasmin
  • Others

By Application

  • Hormonal Infertility
  • Postmenopausal Osteoporosis
  • Endometriosis
  • Contraceptives
  • Menopause
  • Polycystic Ovary Syndrome
  • Other application

By Region

  • America
    • North America
      • The U.S.
      • Canada
      • South America
  • Europe
    • Western Europe
      • Germany
      • The U.K.
      • France
      • Italy
      • Spain
    • Eastern Europe
    • The Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Korea
    • Australia
    • South Korea
    • The Rest of Asia-Pacific
  • The Middle East and Africa

Frequently Asked Questions (FAQs)

A growing number of aging women across the globe, increasing chronic illness in women, growing demand for contraceptives to prevent unintended pregnancies are the key factors expected to drive Women’s Health Care Market during the forecast period.
Amgen Inc., Pfizer Inc., Bayer AG, Merck & Co., Allergan, Eli Lilly And Company, AMAG Pharmaceuticals, Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson are the top players in Women’s Health Care Market.
North America is expected to hold the highest market share in Women’s Health Care Market.
Prolia Drug Segment is expected to be the leading segment in Women’s Health Care Market during the forecast period.
The women’s health care market is predicted to grow with a CAGR of 14.0% during the forecast period.
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times and included in every purchase.
We will send you an email with login credentials to access the report. You will also be able to download the pdf.
Basically, choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.